Parabilis Medicines
Coverage of Parabilis Medicines in the Nexus archive.
- Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO
Parabilis Medicines, a Cambridge, Massachusetts-based biotech, is raising $670 million in its IPO by pricing 33.5 million shares at $20 each, surpassing Kailera Therapeutics' previous record of $625 million raised in April.
- STAT+: Hope for Kendall Square’s lab market
Sanofi halted a Phase 3 study of its drug riliprubart due to lack of efficacy, while Parabilis Medicines raised $670 million in a record biotech IPO. European countries face conflicts over drug-pricing policies amid budget strains and U.S. pressure.
- STAT+: Drugmakers guard IP more tightly amid China competition
Parabilis Medicines has filed to go public under the symbol PBLS. Former FDA commissioner David Kessler expressed confidence in Kyle Diamantas, the new interim FDA chief. The development comes amid increased competition from China in the biotech industry.